Skip to main content

Table 1 Data of 447 melanoma patients from TCGA

From: UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways

Characteristics N Percentages Characteristics N Percentages
T Clark level
 Ti 7 1.75  I/II/III 98 31.72
 T1 41 10.28  IV/V 211 68.29
 T2 76 19.05 Ulceration
 T3 89 22.31  No 144 47.37
 T4 144 36.09  Yes 160 52.63
N Cancer status
 N0 222 59.04  Tumor free 210 49.64
 N1 73 19.41  With tumor 213 50.35
 N2 49 13.03 New tumor event
M  No 110 25.23
 M0 402 95.04  Yes 326 74.77
 M1 21 4.96 Race
Stage  Asian 11 2.51
 Stage0 6 1.49  White 427 97.49
 Stage1 76 18.81 Age
 Stage2 133 32.92  < 60 237 53.02
 Stage3 169 41.83  ≥ 60 210 46.98
 Stage4 20 4.95 Site
 Extremities 191 49.35
 Head and neck 32 8.27
 Trunk 164 42.38
  1. Patient characteristics included TNM stage, clinical stage, Clark level, ulceration, cancer status, new tumor event, race, age and site were identified